SHARING OPTIONS:
Feeding 200g to 300g/head/day is typically sufficient to boost colostrum quality where silage quality is quite poor.
The level of protein in the diet of the cow for the last few weeks prior to calving will have a huge influence on both the amount and quality of the colostrum the cow produces.
While feeding soya for the final two to three weeks prior to calving is a great way to increase the overall protein level of the diet and therefore colostrum quality, there are certain situations where the benefit of feeding soya pre-calving should be questioned.
Ngày 19-1: Hoàn thành công tác trang trí cây hoa, cây cảnh
baomoi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baomoi.com Daily Mail and Mail on Sunday newspapers.
Θρήνος στην Ισπανία: Πέθανε ο Βιθέντε Καντατόρε - PatrisNews - Εφημερίδα Πατρίς Ηλείας
patrisnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from patrisnews.com Daily Mail and Mail on Sunday newspapers.
NuCana plc: NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
Safety Profile Continues to be Favorable
EDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.
NuTide:302 is a three-part study investigating NUC-3373, NuCana s targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373 s optimal dose and schedule in combination with agents commonly used to treat patients with colorectal cancer and is assessing safety, pharmacokinetics and anti-cancer activity. NUC-3373 has been designed to overcome the main challenges associated with 5-FU and capecitabine, including cancer-resistance mechanisms which limit efficacy, off-target toxicity and administration burdens.
The Cancer Microbiome Atlas gives clearer picture of microbiota living in organs
Biomedical engineers at Duke University have devised an algorithm to remove contaminated microbial genetic information from The Cancer Genome Atlas (TCGA). With a clearer picture of the microbiota living in various organs in both healthy and cancerous states, researchers will now be able to find new biomarkers of disease and better understand how numerous cancers affect the human body.
In the first study using the newly decontaminated dataset, the researchers have already discovered that normal and cancerous organ tissues have a slightly different microbiota composition, that bacteria from these diseased sites can enter the bloodstream, and that this bacterial information could help diagnose cancer and predict patient outcomes.